肽疫苗。

Peptide vaccine.

机构信息

Department of Neurosurgery, Hyogo College of Medicine, Hyogo, Japan.

出版信息

Adv Exp Med Biol. 2012;746:166-77. doi: 10.1007/978-1-4614-3146-6_13.

Abstract

Current combinations of surgical therapy, radiotherapy and chemotherapy regimens do not significantly improve long-term survival of the patients with malignant glioma. Cancer immunotherapy against malignant glioma is a potentially new therapeutic strategy that primes a patient's immune system to attack glioma cells. Peptide-based vaccination appears promising as an approach to successfully induce an antineoplastic immune response, produce clinical response and prolong survival in patients with malignant glioma without major side effects. In this chapter, clinical progress is reviewed in developing peptide-based vaccinations for malignant glioma to date.

摘要

目前，手术治疗、放疗和化疗方案的联合应用并没有显著改善恶性脑胶质瘤患者的长期生存率。针对恶性脑胶质瘤的癌症免疫疗法是一种潜在的新治疗策略，可以使患者的免疫系统攻击脑胶质瘤细胞。基于肽的疫苗接种作为一种成功诱导抗肿瘤免疫反应、产生临床反应并延长恶性脑胶质瘤患者生存而无重大副作用的方法似乎很有前景。本章回顾了迄今为止用于恶性脑胶质瘤的基于肽的疫苗接种的临床进展。